ASH 2020 | MPNs: a changing treatment landscape
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, discusses highlights in the field of myeloproliferative neoplasms (MPNs) at ASH 2020. Firstly, he outlines the progress made in the understanding of the pathogenesis of MPNs, including the identification of driver mutations which can occur as early as in utero. Dr Yacoub goes on to discuss the inclusion of overall survival as an endpoint in various clinical trials, a concept that was previously lacking in the field of myelofibrosis. Finally, Dr Yacoub highlights how ongoing clinical trials testing agents including the PI3Kδ inhibitor parsaclisib, a BIT inhibitor and a BCL-xL inhibitor as frontline therapies could change the landscape of MPN treatment in the future. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
